Cancer Center News

Your child will be cared for by one of the most accomplished teams of childhood cancer experts in the world. We provide medical care, emotional counseling and much more. We make sure your child, you and every family member get the highest level of support.

Existing patients or family members
New patients, referrals and second opinions

Researchers at Children’s Hospital of Philadelphia Highlight Role of Alternative Splicing in Chemotherapy Resistance
Researchers at Children’s Hospital of Philadelphia (CHOP) have elucidated the significant role that alternative splicing – a process whereby a single gene produces multiple proteins by rearranging its messenger RNA segments in different combinations – plays in resistance to chemotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The study published today in the journal Cancer Research.
Bernadette, 10, CHOP neuroblastoma patient

New Avenues

Sep 24, 2024
CHOP researchers are aiming to treat a wider range of cancers by reaching previously “unreachable” drug targets.

Children’s Hospital of Philadelphia Researchers Find Promising Preclinical Results for High-Risk Neuroblastoma

Sep 4, 2024
Researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated a promising new approach in the fight against high-risk neuroblastoma, a common and potentially deadly childhood cancer that can occur within the peripheral nervous system. The study, recently published in Nature Communications, found that chimeric antigen receptor (CAR) T-cell therapy targeting two markers on neuroblastoma cancer cells simultaneously boosted overall immune response by engaging adaptive and innate immunity in preclinical models.

New Research from Children’s Hospital of Philadelphia and St. Jude Poised to Transform Approach to Diagnosing and Treating Acute Leukemia in Children

Aug 14, 2024
Researchers at Children’s Hospital of Philadelphia (CHOP), St. Jude Children’s Research Hospital (St. Jude) and the Children’s Oncology Group (COG) today announced a significant paradigm shift in the understanding of T-lineage acute lymphoblastic leukemia (T-ALL), an aggressive and high-risk form of cancer, to one frequently driven by genetic changes in non-coding portions of our DNA. The collaborative study, supported by the Gabriella Miller Kids First Pediatric Research Program (Kids First) and National Institutes of Health (NIH) Common Fund, was published today in the journal Nature.